Oxford BioMedica plc (OXB) Raised to Hold at N+1 Singer
Oxford BioMedica plc (LON:OXB) was upgraded by investment analysts at N+1 Singer to a “hold” rating in a note issued to investors on Friday.
Shares of Oxford BioMedica plc (LON:OXB) opened at 3.129 on Friday. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 8.45. The stock has a 50 day moving average price of GBX 3.65 and a 200-day moving average price of GBX 4.64. The stock’s market capitalization is GBX 83.38 million.
In other Oxford BioMedica plc news, insider Lorenzo Tallarigo purchased 79,988 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £2,399.64 ($2,969.85). Also, insider Tallarigo ,Lorenzo purchased 62,257 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The shares were acquired at an average cost of GBX 4 ($0.05) per share, with a total value of £2,490.28 ($3,082.03).
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/oxford-biomedica-plc-oxb-rating-increased-to-hold-at-n1-singer.html
About Oxford BioMedica plc
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.